Conclusions: SAXA showed promising anti-cancer action against A549 cells. Although the combination with CP did not boost cytotoxicity, the observed pro-apoptotic reduction in BCL2 implies potential therapeutic efficacy.
Shubbar et al. (Fri,) studied this question.